Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9969420 | 0.89 | SSTR4 (0.49) | HTR1AHTR1DHTR1BMCHR1IDO1 | |
| SCHEMBL23412378 | 0.85 | MAPT (0.52) | HTR1AHTR1DHTR1BNR3C1NCF1 | |
| SCHEMBL23412188 | 0.83 | NCF1 (0.51) | HTR1AHTR1DHTR1BNCF1KDM4E | |
| SCHEMBL9969535 | 0.82 | HTR1B (0.48) | HTR1AHTR1DHTR1BMCHR1NR3C1 | |
| SCHEMBL29872827 | 0.82 | HTR1B (0.48) | HTR1AHTR1DHTR1BMCHR1NR3C1 | |
| SCHEMBL23412437 | 0.82 | NCF1 (0.58) | HTR1AHTR1DHTR1BNCF1KDM4E | |
| SCHEMBL827493 | 0.81 | HTR1B (0.47) | HTR1AHTR1DHTR1BMCHR1NCF1 | |
| SCHEMBL23412394 | 0.80 | NCF1 (0.59) | NCF1KDM4EMAPT | |
| SCHEMBL12958275 | 0.80 | MCHR1 (0.48) | HTR1DHTR1BMCHR1IDO1SLC6A4 | |
| SCHEMBL23412668 | 0.80 | NCF1 (0.59) | NCF1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11377428-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370765-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11332451-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (GA) | 2022-05-17 | — | — | US | disclosed |
| US-20210238153-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | HTR1A 4292/4885HTR1D 4628/4885HTR1B 4433/4885 |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | HTR1A 3055/4885HTR1D 2009/4885HTR1B 2753/4885 |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | HTR1A 3055/4885HTR1D 2009/4885HTR1B 2753/4885 |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIPK1, RIPK2, RIPK3 | HTR1A 4292/4885HTR1D 4628/4885HTR1B 4433/4885 |
| US-20210238153-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | HTR1A 4292/4885HTR1D 4628/4885HTR1B 4433/4885 |
| US-11377428-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | HTR1A 4292/4885HTR1D 4628/4885HTR1B 4433/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | HTR1A 2833/4885HTR1D 3378/4885HTR1B 2039/4885 |
| US-11332451-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | HTR1A 4292/4885HTR1D 4628/4885HTR1B 4433/4885 |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | HTR1A 4292/4885HTR1D 4628/4885HTR1B 4433/4885 |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | HTR1A 4292/4885HTR1D 4628/4885HTR1B 4433/4885 |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | HTR1A 4292/4885HTR1D 4628/4885HTR1B 4433/4885 |
| US-11370765-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | HTR1A 4292/4885HTR1D 4628/4885HTR1B 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.